James Stough, DPM
Podiatrist · Enid, OKNPI 1003043423
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.3%), consulting fees and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by In2bones USA, LLC at 38.7% of the total. Reporting peaked in 2021 at $2,282 and has fallen 86.9% since, to $299 in 2025.
Across 39 payments — averaging $135.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- In2bones USA, LLC$2K
- Pylant Medical$2K
- Medtronic$610
- Zimmer Biomet$291
- Stryker$207
- Trice Medical, Inc.$165
- plus $282 from 7 others
What the payments were for
- Consulting fees$2,00038%
- Food & beverage$2,07239%
- Education$1,20023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| In2bones USA, LLC | 4 | $2,040 |
| Pylant Medical | 7 | $1,676 |
| Medtronic | 15 | $610 |
| Zimmer Biomet | 2 | $291 |
| Stryker | 3 | $207 |
| Trice Medical, Inc. | 1 | $165 |
| Tenex Health Inc. | 1 | $154 |
| Arthrex | 1 | $60 |
| Treace Medical Concepts, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Solventum Corporation | 1 | $15 |
| Merck | 1 | $14 |
| Organogenesis Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoLink$2,000
- Stratum Foot Plating System$291
- INTELLIS ADAPTIVESTIM$279
- AUGMENT INJECTABLE$142
How this compares
$5,272 in reported general payments places this provider in the 80th percentile of 54 podiatrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 22 | $602 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 53 | $424 |
| Cephalexin | 50 | $406 |
| Ondansetron OdtOndansetron | 50 | $286 |
| Clindamycin Hcl | 16 | $262 |
| Methylprednisolone | 29 | $258 |
| Meloxicam | 34 | $199 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 32 | $128 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Enid
- Scott ShieldsEnid$5K
- David CavallaroOklahoma City$22K
- Ahmed BukshEdmond$17K
- Aerial AveryAda$13K
- Patricia BoehleOklahoma City$10K
- Kevin DuxMuskogee$8K
- Barinder BassiTahlequah$7K
- Greg RohdeNorman$7K
- Thomas WicksChickasha$6K
- Tera SantistevanSapulpa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.